Lisata Therapeutics Inc. to Report Q1 2025 Financial Results
Basking Ridge, N.J., May 1, 2025 — Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its plans to release its financial results for the first quarter of 2025. The company will report these results on Thursday, May 8, 2025, following the close of trading. Additionally, Lisata will host a conference call at 4:30 p.m. Eastern time to provide a comprehensive business update.
Conference Call Details
Those interested in participating in the conference call are encouraged to register in advance through the provided link. Registered participants will receive an email with the necessary dial-in details. To ensure a smooth experience, it is recommended that participants join the call 15 minutes prior to the scheduled start time. A live webcast of the call will be accessible under the Investors & News section of Lisata’s website, with a replay available for 12 months starting two hours after the call concludes.
Company Overview
Lisata Therapeutics operates within the biotechnology sector of the health care industry, specializing in the development of products targeting cardiovascular and autoimmune diseases. As a Nasdaq-traded company, Lisata has a market capitalization of $21,030,000 and trades in USD. Despite a challenging financial landscape, as indicated by a negative price-to-earnings ratio of -1.05, Lisata remains committed to its mission of discovering, developing, and commercializing innovative therapies.
Financial Highlights
As of April 29, 2025, Lisata’s stock closed at $2.37, reflecting a significant fluctuation over the past year, with a 52-week high of $4.2 on January 5, 2025, and a low of $1.87 on April 6, 2025. The company continues to navigate the complexities of the biotechnology sector, focusing on its promising product candidate, cert, a cyclic peptide aimed at treating advanced solid tumors.
Forward-Looking Perspective
As Lisata prepares to disclose its Q1 2025 financial results, investors and stakeholders are keenly anticipating insights into the company’s progress and strategic direction. The upcoming conference call is expected to shed light on Lisata’s ongoing efforts to advance its pipeline and enhance its market position. With a steadfast commitment to innovation and patient care, Lisata Therapeutics is poised to make significant strides in the biopharmaceutical landscape.
For more information about Lisata Therapeutics and its offerings, visit their website at www.caladrius.com .